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Introduction
Ageing is characterised by an increase in the prevalence of frailty, conceptualised by deterioration of multiple organ systems leading to loss of physiological reserve, diminished capacity to cope with stressors, and increased risk of disability and death [1, 2] . One definition of frailty utilises the presence of three or more of five components: unintentional weight loss, exhaustion, poor grip strength, slow walking speed, or low physical activity [1] .
The FRAIL scale has been proposed as an alternative tool for screening for frailty [3] . This utilises five elements of Fatigue, Resistance, Ambulation limitation, Illnesses, and Loss of weight, with frailty represented by the presence of three or more of these elements. Both scales reflect the presence of sarcopenia, or loss of lean muscle mass, which in turn leads to decreased muscle function which is regarded as a key factor in the development of frailty.
The underlying mechanisms that contribute to development of frailty as people age remain poorly understood. Insulin-like growth factor-I (IGF-I) is an anabolic hormone that regulates body composition and maintains muscle mass [4] . Ageing is associated with a decline in pituitary growth hormone secretion, resulting in reduced liver production of insulin-like growth factor-I (IGF-I) [5] . The bioavailability of IGF-I is modulated by binding to circulating IGF-binding proteins (IGFBPs), with the majority of circulating IGF-I carried within a ternary complex bound to IGFBP3 and the acid labile subunit (ALS) [6] . IGFBP1 binds a smaller fraction of plasma IGF-I, but in a manner responsive to metabolic status [7] .
Insulin suppresses hepatic IGFBP1 synthesis, decreasing the amount available for binding
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© 2012 Blackwell Publishing Ltd IGF-I and accounting for the association of reduced IGFBP1 with insulin resistance or the metabolic syndrome [8] . IGF-I has been investigated as a potential contributor to risk of frailty in women [9, 10] . However, despite its role as an anabolic hormone and its decline with age, there are limited data exploring the role of circulating IGF-I and its binding proteins in the genesis of frailty in ageing men.
We have previously shown that examining different components of the IGF-I system can be more informative than analysing circulating levels of IGF-I alone [11] . Therefore we examined associations of IGF-I and its binding proteins IGFBP1 and IGFBP3 with frailty in a population-based cohort of community-dwelling older men. Testosterone is another anabolic hormone [12] . As lower testosterone levels are associated with frailty [13] , we assessed whether stratifying by both IGF-I and testosterone levels would identify men most at risk of being or becoming frail. Additionally, indices of insulin resistance are predictors of frailty [14] , prompting us to exclude men with metabolic syndrome in a supplementary analysis.
Methods

Study population
The Health In Men Study (HIMS) is a longitudinal study of men who originally participated in a trial of screening for abdominal aortic aneurysm [15] . Briefly, between 1996-99 (wave 
Assessment of frailty
Frailty was assessed at W2 and at W3 using the FRAIL scale [3] . This screening tool assesses five domains: Fatigue, Resistance, Ambulation, Illnesses, and Loss of weight.
Fatigue, resistance and ambulation were assessed from responses to the SF-36 Health Survey [16] . Participants scored positive for Fatigue if they responded "all of the time", "most of the time", or "a good bit of the time" to the questions "did you feel worn out?" or "did you feel tired?", or answered "some of the time", "a little of the time", or "none of the time" to the question "did you have a lot of energy?". Deficits were recorded for Resistance or Ambulation if participants reported that they were "limited a lot" or "limited a little" in their ability to climb one flight of stairs, or walk 100 metres respectively. A deficit was recorded for Illness if the participant reported more than 5 of the following: arthritis, diabetes, angina or myocardial infarction, hypertension, stroke, asthma, chronic bronchitis, emphysema, osteoporosis, colorectal cancer, skin cancer, depression or an anxiety disorder, Alzheimer's disease or other dementia, or leg ulcers. Participants scored positive for Loss of weight if their weight decreased by more than 5% between W1 and W2, or between W2 and W3. Men were classified as being frail if they presented problems in three or more of these five domains.
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Assessment of medical comorbidities
Questionnaire responses were utilised to collect data on medical comorbidities. Smoking history was categorised as current, ex-smoker or life-long non-smoker. Hypertension was defined as a recorded blood pressure ≥140/90 or having a diagnosis of hypertension or receiving treatment for high blood pressure. Dyslipidemia was defined as having HDL <0.9 mmol/L, LDL ≥3.4 mmol/L, triglycerides ≥1.8 mmol/L or total cholesterol ≥5.5 mmol/L, or receiving lipid-lowering therapy. Diabetes was defined as having been diagnosed with or receiving treatment for diabetes, fasting glucose level >7 mmol/L or non-fasting glucose >11.1 mmol/L. Cardiovascular disease (CVD) was defined as history of angina, acute myocardial infarction or stroke by questionnaire responses, or hospital diagnoses of these conditions prior to Wave 2. Additional information on medical co-morbidities was obtained from the Western Australian Data Linkage System which links together records from the Mental Health Information System, cancer register, death register and hospital morbidity data [17] .
Laboratory assays
Blood samples were collected between 0800 and 1030 hours. Plasma was prepared immediately following phlebotomy and stored at -80 o C until assayed. Hormone assays were performed as previously described [11] . Briefly, total IGF-I, IGFBP1 and IGFBP3 were assayed using reagent kits of single lot numbers from Diagnostics Systems Laboratories Inc Testosterone results measured by immunoassay in this cohort have been previously reported, as have calculated free testosterone values [18] . Coefficient of variation for testosterone was 11.2% at 7.2 nmol/l and 8.9% at 18 nmol/l [18] .
Statistical analysis
Data were analysed with the statistical package Stata, version 11.2 (StataCorp, 2011).
Continuous variables were presented as mean ± standard deviation (SD) and comparisons performed using Student's t-test. Nominal variables were presented as percentages (%) and compared with the Chi-squared test. Logistic regression analysis was used to assess odds ratio for frailty according to quartiles of IGF-I, IGFBP1 or IGFBP3. To determine if there were trends across quartiles of IGF-I, IGFBP1 and IGFBP3, the data were tested for linearity and entered as a continuous variable in the model. A trend was considered to exist if the odds ratio for these quartiles when entered as a continuous variable was significantly different from 1 (p<0.05). Regression analyses were adjusted for age, BMI, smoking, fasting status at time of blood collection and diabetes. Cross-sectional analyses were conducted to test associations of IGF-I and its binding proteins with presence of frailty at W2. Longitudinal analyses were performed after excluding men with frailty at W2, to test associations of IGF-I and its binding proteins with new onset of frailty at W3. As men with lower total IGF-I and higher IGFBP1 levels might be expected to have less bioavailable IGF-I, associations with frailty were examined after stratifying men accordingly. Finally, logistic regression models were used to assess risk of frailty for men with both IGF-I and free testosterone levels in the 
Results
IGF-I, IGFBP3 and IGFBP1 levels in frail men
Of 4,249 men who were assessed at W2, after excluding men for whom suitable plasma aliquots could not be retrieved and men with incomplete data, IGF-I, IGFBP1 and IGFBP3 data were available for 3,970 men. Descriptive data from this cohort have been published previously showing that IGF-I and IGFBP3 levels were negatively correlated with increasing age, while IGFBP1 levels were positively correlated [11] . We then excluded 333 men who reported use of testosterone, hormonal therapies interfering with androgen production or action, and prostate cancer. Another 190 men had incomplete data, leaving 3,447 men for the analysis. Demographic, physical and biochemical data for these men are shown in Table 1. 527 men were classified as frail at baseline (15.3%), and these men had comparable IGFBP1 and lower IGFBP3 levels compared with men who were not.
Associations of IGF-I, IGFBP1 and IGFBP3 with prevalent frailty
In univariate analyses, higher IGFBP3 was associated with reduced odds ratio (OR) of frailty (highest vs lowest quartile, Q4:Q1 OR=0.59, 95% confidence interval [CI]=0.46-0.77, p<0.001 for trend) ( Table 2 ). However, this association was attenuated after adjustment for covariates. In the multivariate analysis, higher IGFBP1 was associated with increased OR for frailty (Q4:Q1: adjusted OR=1.39, 95%CI=1.03-1.88, p=0.035 for trend).
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Associations of IGF-I, IGFBP1, IGFBP3 and IGF-I/IGFBP3 with new onset frailty
Of the 3,447 men in the cross-sectional analysis, 2,959 were alive at W3. Of these, 1,654 completed and returned the questionnaire at W3. Men who did not respond were older (77.6 vs 75.6 years, p<0.001) and more likely to be frail (14.9 vs 10.9%, p=0.001) at W2.
Excluding 170 men who were frail at W2 there were 1,484 men for the longitudinal analysis, aged 76-93 years at W3. 260 of these men who were not frail at W2 had become frail at W3 (17.5%). In univariate analysis, lower IGF-I level was associated with increased risk of new onset frailty (Q1:Q4 OR=1.66, 95%CI=1.13-2.43, p=0.015 for trend). Higher IGFBP3 was associated with reduced risk (p=0.038 for trend) (Table 3 ). However, following adjustment for covariates both these associations were attenuated. There were trends toward an association between lower IGF-I and increased odds of new onset frailty (Q1:Q4, adjusted OR=1.48, 95%CI=1.00-2.20, p=0.081 for trend) and higher IGFBP1 and increased odds of new onset frailty (Q4:Q1, adjusted OR=1.59, 95%CI=1.01-2.50, p=0.085 for trend).
Stratification by low IGF-I and high IGFBP1 level
To investigate these trends further, we stratified men according to IGF-I level in the highest quartile and IGFBP1 in the lowest (>173 and <11.8 ng/ml respectively), IGF-I in the lowest quartile and IGFBP1 in the highest (<103 and >32.9 ng/ml respectively) with the remaining men as the reference group (Table 4 ). The interaction term for IGF-I and IGFBP1 was not significant (z=0.52, p=0.604). In the multivariate analysis, men with IGF-I <103 ng/ml and IGFBP1 >32.9 ng/ml possessed a two-fold increased risk for new onset frailty (adjusted OR=2.08, 95%CI=1.22-3.53).
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Stratification by low IGF-I and low free testosterone level
To assess whether men with both low IGF-I and low free testosterone levels would have the greatest risk of being or becoming frail, we stratified men using thresholds for the lowest quartile of IGF-I (<103 ng/ml) and the lowest quartile for free testosterone (<222 pmol/L) ( Table 5 ). In univariate analyses, men with both IGF-I and testosterone values in the lowest quartiles had increased odds of being frail at baseline (OR=2.90, 95%CI=2.14-3.94). In multivariate analyses the association of low IGF-I and low testosterone with prevalent frailty remained (OR=2.13, 95%CI=1.54-2.95). There was a significant interaction between IGF-I and free testosterone in the analysis of frailty at baseline (z=-3.45, p=0.001). Men with both low IGF-I and free testosterone were more likely to be frail compared to men with low free testosterone alone (OR=1.45, 95%CI=1.01-2.07, p=0.04).
There was no significant association of low IGF-I and low testosterone with new onset frailty in univariate (OR=1.53, 95%CI 0.85-2.75) or multivariate analyses (OR=1.12, 95%CI=0.59-2.10). In the adjusted analysis, men with low IGF-I and normal free testosterone were more likely to become frail (OR=1.50, 95%CI=1.05-2.15).
Supplementary analysis
Insulin resistance is associated with lower IGFBP1, and men with low IGFBP1 are more likely to have metabolic syndrome [8, 11] . To examine whether presence of metabolic syndrome might confound the association of IGFBP1 with frailty, we performed a sensitivity analysis excluding all men with metabolic syndrome. Metabolic syndrome was defined according to the NCEP-ATPIII classification as 3 or more of: waist circumference >102 cm, fasting plasma glucose ≥5.6 mmol/L or a known diagnosis of diabetes, fasting serum
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© 2012 Blackwell Publishing Ltd triglycerides ≥1.7 mmol/L, fasting HDL cholesterol <1.03 mmol/L or blood pressure ≥130/85 mmHg [11] . In multivariate analysis, higher IGFBP1 remained associated with increased odds of frailty at baseline (Q4:Q1 adjusted OR=1.63, 95%CI=1.07-2.47, p=0.017 for trend).
Discussion
We found that there was no independent association of either IGF-I or IGFBP3 with prevalent frailty or new onset of frailty in community-dwelling older men. However, men with higher IGFBP1 levels were more likely to be frail, while those with either IGF-I in the lowest quartile or IGFBP1 in the highest quartile were more likely to become frail. Men with both lower IGF-I and lower free testosterone levels were more likely to be frail.
These results are relevant as previous studies have suggested a role for IGF-I in the maintenance of muscle mass and prevention of sarcopenia [4] . IGF-I mediates growth and repair in skeletal muscle, hence the expectation that lower IGF-I levels might predispose to frailty (for review, see [19] ). However, GH supplementation at a dose sufficient to increase circulating IGF-I did not enhance the improvement in muscle strength following exercise training in older men [20] . A systematic review of GH therapy in healthy older adults concluded that the available data were limited, with GH treatment resulting in modest decreases in fat mass and increases in lean body mass [21] . A previous study of 494 women aged 70-79 years reported an increased odds ratio for frailty in those with IGF-I in the lowest quartile, which did not reach statistical significance [9] . A cross-sectional analysis reported a bivariate U-shaped association: compared to women with low white blood cell (WBC) counts and high IGF-I levels defined by tertiles, women with low WBC counts and low IGF-I levels, high WBC counts and low IGF-I, and high WBC and high IGF-I levels had
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Lower circulating IGF-I has been associated with an increased risk of heart failure and occlusive atherosclerotic disease such as stroke and coronary heart disease [22] [23] [24] . Lower IGF-I levels have also been associated with all-cause or CVD-related mortality [25, 26] . A recent meta-analysis reported a U-shaped association of IGF-I with mortality, with increased mortality associated with low and high IGF-I levels (10 th vs 50 th and 50 th vs 90 th percentiles,
[27]). However, the hazard ratios were modest (1.56 and 1.29 respectively). Published studies are not wholly consistent, for instance in this cohort we found no independent association of IGF-I levels with either all-cause or cardiovascular mortality [28] . We did find that lower and higher IGF-I and IGFBP3 levels were associated with metabolic syndrome [11] , which is consistent with the findings of the meta-analysis with respect to mortality [27] . Therefore the IGF-I system may contribute to, or be a biomarker for, cardiovascular disease in ageing. However, circulating IGF-I in isolation is not closely associated with the outcome of frailty.
In this study lower IGFBP1 levels were associated with lower odds of frailty at baseline.
Lower IGFBP1 levels are associated with metabolic syndrome, but this association remained unchanged after exclusion of all men with metabolic syndrome who would be expected to have a greater degree of insulin resistance. Therefore, the finding is unlikely to be due to confounding from this source. We postulate that lower IGFBP1 levels might reflect reduced binding capacity for IGF-I and therefore the presence of increased proportions of unbound or bioavailable IGF-I, and that this fraction of IGF-I could be the most relevant [7, 26] . Of note,
© 2012 Blackwell Publishing Ltd men with both lower IGF-I and higher IGFBP1 levels were significantly more likely to become frail, showing a two-fold increased risk in the multivariate analysis. Thus higher IGFBP1, or the combination of lower IGF-I and higher IGFBP1, could reflect reduced levels of bioavailable or bioactive IGF-I and loss of its anabolic action predisposing to sarcopenia.
It is also possible that IGFBP1 may act independently of IGF-I on a cellular level to influence specific tissues [29] . Higher IGFBP1 levels have been associated with increased all-cause and cardiovascular mortality [28, 30, 31] . Therefore, further studies are needed to clarify whether IGFBP1 is a biomarker or a causal factor for divergent health outcomes including frailty. Additional studies are also required to explore the interaction of IGFBP1
and IGF-I levels on other health outcomes.
Lower testosterone levels are associated with frailty in both cross-sectional and longitudinal analyses from this cohort and elsewhere [13, 32] . The combination of both testosterone and GH therapy appears to additively increase lean body mass and reduce fat mass when compared to either agent alone [33, 34] . Therefore men with both low IGF-I and low testosterone levels could be most at risk for frailty. We demonstrated that men with low IGF-I and low free testosterone levels were more likely to be frail, but not more likely to become frail over time. We offer two explanations for this observation. The combination of low testosterone and low IGF-I may be a biomarker for existing frailty, rather than an independent predictor of its onset de novo. If so, underlying ill-health may be a common factor underlying both low anabolic hormone levels and frailty. Alternatively, it is possible that the reduced number of men re-assessed in 2008-09 might have resulted in inadequate statistical power to demonstrate a longitudinal association of low testosterone and low IGF-I levels with frailty. Of note, in this analysis men with low IGF-I and normal free testosterone
© 2012 Blackwell Publishing Ltd had a significantly increased risk of becoming frail, supporting the relevance of the IGF-I system to the development of frailty.
The strengths of this study include the large sample size, the availability of results for both IGF-I and its binding proteins and for testosterone, adjustment for several potential confounders in the multivariate analyses, and the combination of cross-sectional and longitudinal analyses. Study limitations include the fact that the cohort comprised men who returned for assessment and blood sampling from an earlier population-based sample and only a proportion of surviving men responded to the questionnaire at W3. Therefore a "healthy survivor" effect is possible which would make our results more conservative and applicable to generally healthier community-dwelling older men. The limited response at W3 may have reduced our power to detect underlying associations of IGF-I and its binding proteins with new onset frailty. We used a single blood sample, and did not have the capacity to measure free or unbound IGF-I levels either by immunoassay or ultracentrifugation, nor were we able to measure circulating IGF-I bioactivity [26] . Therefore our assessment was limited to circulating total IGF-I, IGFBP1 and IGFBP3. We measured testosterone by immunoassay, and calculated free testosterone values [18] . We used the FRAIL scale to assess frailty, rather than a measure based on the Fried criteria [1] . However, we have shown that the FRAIL scale is a robust predictor of mortality in this cohort of older men [13] . A component of the FRAIL scale is loss of weight, which may be associated gain of insulin sensitivity and therefore with higher IGFBP1 levels [8] , or with higher testosterone levels [35] . If this were the case, it would result in frail men having higher IGFBP1 and testosterone levels, hence would tend to attenuate rather than accentuate the association between low IGFBP1 and low testosterone with frailty.
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